Stocks
Catalyst Pharmaceuticals IncCPRX
NASDAQHealthcareBiotechnology$31.49
Price as of · delayed, not real-time
A commercial-stage biopharmaceutical company focused on developing and commercializing therapies for rare neuromuscular and neurological diseases. Its lead product, Firdapse, treats Lambert-Eaton myasthenic syndrome, and the company has expanded its pipeline through acquisitions. Investors track it for its orphan drug portfolio and revenue growth in a niche market.
52W Range: $19.05-$32.56
Congressional Interest in Catalyst Pharmaceuticals Inc (CPRX)
2 members of Congress have disclosed 3 trades in Catalyst Pharmaceuticals Inc (CPRX), a Healthcare company. The buy/sell breakdown shows 3 purchases versus 0 sales, indicating net buying interest from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
3
Unique Politicians
2
Buys
3
Sells
0
Who in Congress Is Trading CPRX?
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2025-04-15 | Rohit Khanna | buy | $1K-$15K |
| 2021-09-07 | MICHAEL T. MCCAUL | buy | $1K-$15K |
| 2021-06-07 | MICHAEL T. MCCAUL | buy | $1K-$15K |